Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

VTRS

Viatris Inc

Mar 27 • 11:55AM ET

13.32

-0.05 -0.37 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: PFE MRK BMY JNJ ABBV GSK LLY AMGN SNY NVS

| Held by: VTI VOO VB VBR IVV SPY RSP XLV COWZ SPYD

Scroll to Statements

Index	S&P 500	P/E	-	EPS (ttm)	-2.96	Insider Own	2.05%	Shs Outstand	1.15B	Perf Week	0.91%
Market Cap	15.34B	Forward P/E	5.02	EPS next Y	2.66	Insider Trans	-0.09%	Shs Float	1.13B	Perf Month	-12.66%
Enterprise Value	28.58B	PEG	0.53	EPS next Q	0.50	Inst Own	84.19%	Short Float	2.51%	Perf Quarter	8.82%
Income	-3.51B	P/S	1.07	EPS this Y	4.04%	Inst Trans	0.39%	Short Ratio	2.75	Perf Half Y	40.36%
Sales	14.29B	P/B	1.04	EPS next Y	8.60%	ROA	-8.93%	Short Interest	28.32M	Perf YTD	6.99%
Book/sh	12.78	P/C	10.54	EPS next 5Y	9.42%	ROE	-21.08%	52W High	16.47 -19.13%	Perf Year	50.68%
Cash/sh	1.26	P/FCF	7.92	EPS past 3/5Y	- -21.93%	ROIC	-12.84%	52W Low	6.85 94.45%	Perf 3Y	40.65%
Dividend Est.	0.52 (3.89%)	EV/EBITDA	7.25	Sales past 3/5Y	-4.04% 3.66%	Gross Margin	38.49%	Volatility	2.57% 3.37%	Perf 5Y	-7.24%
Dividend TTM	0.48 (3.60%)	EV/Sales	2.00	EPS Y/Y TTM	-456.43%	Oper. Margin	7.99%	ATR (14)	0.42	Perf 10Y	-70.97%
Dividend Ex-Date	Mar 09, 2026	Quick Ratio	0.74	Sales Y/Y TTM	-2.61%	Profit Margin	-24.59%	RSI (14)	37.23	Recom	2.42
Dividend Gr. 3/5Y	0.00% -	Current Ratio	1.30	EPS Q/Q	31.80%	SMA20	-4.23%	Beta	0.83	Target Price	15.88
Payout	-	Debt/Eq	1.00	Sales Q/Q	6.60%	SMA50	-6.62%	Rel Volume	0.24	Prev Close	13.37
Employees	30000	LT Debt/Eq	0.86	Earnings	Feb 26 BMO	SMA200	18.03%	Avg Volume	10.30M	Price	13.32
IPO	Mar 17, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.08% 4.85%	Trades		Volume	1,003,985	Change	-0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-09-26	Upgrade	UBS	Neutral → Buy	$18
Jan-16-26	Upgrade	Argus	Hold → Buy	$15
Dec-09-25	Initiated	Barclays	Overweight	$15
Oct-15-25	Initiated	Truist	Buy	$15
Jun-06-25	Initiated	Goldman	Neutral	$10
Jul-19-24	Resumed	Jefferies	Buy	$15
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $9
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight	$11
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight	$11
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$16 → $14
Jan-27-23	Upgrade	Jefferies	Hold → Buy	$13 → $15
Nov-10-22	Upgrade	UBS	Sell → Neutral	$9 → $12
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral	$10
Oct-21-22	Resumed	Jefferies	Hold	$11
Jun-14-22	Initiated	UBS	Sell	$9
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight	$10
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $13
Jun-15-21	Initiated	Citigroup	Neutral	$16
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$24

Show Previous Ratings

Mar-23-26 06:59AM	Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) (PR Newswire)
Mar-19-26 08:30AM	Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 (PR Newswire)
Mar-10-26 12:02AM	Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Mar-04-26 09:40AM	Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Mar-03-26 05:25AM	Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value (Insider Monkey) -5.16%
10:34PM	Loading…
Mar-02-26 10:34PM	Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 (StockStory) +5.16%
Feb-28-26 12:40PM	UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve (Insider Monkey)
Feb-27-26 07:02AM	Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date (Insider Monkey)
Feb-26-26 04:08PM	Viatris Inc (VTRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives (GuruFocus.com)
02:24PM	Analyst Report: Viatris Inc. (Morningstar Research)
11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks)
10:00AM	Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:55AM	Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
08:37AM	Viatris forecasts 2026 profit below estimates on India manufacturing woes (Reuters)
07:27AM	Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 (StockStory)
07:10AM	Loading…
07:10AM	Viatris: Q4 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results (PR Newswire)
06:55AM	Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend (PR Newswire)
Feb-25-26 06:59AM	FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia (PR Newswire)
Feb-24-26 10:24PM	Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow (StockStory)
08:02AM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? (Zacks)
Feb-23-26 09:15AM	Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
09:07AM	What's in Store for These 5 Medical Companies This Earnings Season? (Zacks)
09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-19-26 10:00AM	Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline (Zacks)
Feb-18-26 03:54AM	UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade (Insider Monkey)
Feb-10-26 06:41AM	Where is Viatris Inc. (VTRS) Headed According to the Street? (Insider Monkey)
Feb-09-26 04:34PM	Stocks Settle Higher on Strength in Tech (Barchart)
03:31PM	Why Viatris (VTRS) Stock Is Up Today (StockStory)
Feb-06-26 07:00PM	Women Are One Patch Away From Menopause Reliefif Only They Could Find It (The Wall Street Journal)
04:34PM	Loading…
Feb-03-26 04:34PM	Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 (PR Newswire)
08:30AM	Viatris Appoints Matthew J. Maletta as Chief Legal Officer (PR Newswire)
Feb-02-26 08:42AM	What Are Wall Street Analysts' Target Price for Viatris Stock? (Barchart)
Jan-22-26 06:33AM	Viatris Earnings Preview: What to Expect (Barchart)
Jan-21-26 11:02PM	3 Reasons to Sell VTRS and 1 Stock to Buy Instead (StockStory)
Jan-20-26 06:59AM	Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa (Sotagliflozin) for the Treatment of Heart Failure (PR Newswire)
Jan-08-26 09:05AM	Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer (PR Newswire)
Jan-06-26 12:00PM	Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-02-26 09:44AM	Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones (Insider Monkey)
Dec-30-25 05:38PM	Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves (Insider Monkey)
Dec-19-25 12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
Dec-18-25 06:59AM	Viatris Provides Pipeline Update on Four Regulatory Milestones (PR Newswire)
Dec-17-25 06:59AM	Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-15-25 10:33AM	Is Viatris Stock Outperforming the Dow? (Barchart)
Dec-08-25 05:17AM	Viatris signs agreements with Biocon on $815m stake sale (Pharmaceutical Business Review)
Dec-06-25 09:00AM	Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited (PR Newswire)
Dec-04-25 02:08PM	Mark Cuban Takes Aim at FDA Fees (GuruFocus.com)
Nov-24-25 08:00AM	Viatris to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-19-25 03:00AM	European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe (PR Newswire)
Nov-14-25 08:44AM	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
Nov-13-25 08:00AM	Viatris Recognized as One of the Fortune World's Best Workplaces in 2025 (PR Newswire)
Nov-12-25 10:36PM	Reflecting On Generic Pharmaceuticals Stocks' Q3 Earnings: Viatris (NASDAQ:VTRS) (StockStory)
07:00AM	Viatris (VTRS) Jumps 10% on Reaffirmed Growth Targets (Insider Monkey)
Nov-11-25 07:47PM	Analyst Report: Viatris Inc. (Morningstar Research)
03:55PM	Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know (StockStory)
10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks)
Nov-06-25 03:33PM	Analyst Report: Viatris Inc. (Morningstar Research)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
09:30AM	Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:22AM	Viatris's (NASDAQ:VTRS) Q3 Sales Top Estimates (StockStory)
07:10AM	Viatris: Q3 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance (PR Newswire)
Nov-05-25 09:15AM	Countdown to Viatris (VTRS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
08:10AM	Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Nov-04-25 10:13PM	Viatris (VTRS) Q3 Earnings Report Preview: What To Look For (StockStory)
07:09AM	Viatris Stock: Is Wall Street Bullish or Bearish? (Barchart)
06:59AM	Viatris Announces Quarterly Dividend (PR Newswire)
Nov-02-25 11:34PM	3 Stocks Under $50 We're Skeptical Of (StockStory)
Oct-30-25 02:05PM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
10:00AM	Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 09:40AM	Is Viatris (VTRS) Stock Undervalued Right Now? (Zacks)
Oct-24-25 08:42AM	What You Need to Know Ahead of Viatris' Earnings Release (Barchart)
08:07AM	Truist Initiates Viatris (VTRS) Coverage with Buy Rating, $15 PT (Insider Monkey)
Oct-22-25 12:04AM	3 Reasons to Sell VTRS and 1 Stock to Buy Instead (StockStory)
Oct-21-25 12:10PM	Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report? (Zacks)
05:52AM	Viatris Inc. (VTRS) Acquires Aculys Pharma, Inc (Insider Monkey)
Oct-16-25 11:14AM	Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan (Zacks)
Oct-15-25 04:30PM	Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia in Japan and Certain Other Markets in the Asia-Pacific Region (PR Newswire)
Oct-13-25 06:59AM	Viatris to Participate in Upcoming Investor Conferences (PR Newswire)
Oct-09-25 05:10AM	Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials (The Wall Street Journal)
Oct-08-25 11:00AM	Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row (PR Newswire)
Oct-01-25 09:00AM	Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025 (PR Newswire)
Sep-26-25 08:57AM	Is Viatris Stock Underperforming the Nasdaq? (Barchart)
Sep-23-25 07:10PM	Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection (Insider Monkey)
Sep-16-25 09:31AM	Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light (Insider Monkey)
Sep-04-25 03:45AM	Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris (Zacks)
Sep-03-25 11:30AM	Insider Watch: 3 CEOs Buying the Dip (Zacks)
Sep-02-25 12:57PM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
Aug-29-25 05:03AM	Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women's Health (Insider Monkey)
Aug-19-25 11:34PM	Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment (StockStory)
09:00AM	Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer (PR Newswire)
Aug-14-25 01:34AM	5 Must-Read Analyst Questions From Viatris's Q2 Earnings Call (StockStory)
Aug-13-25 12:23AM	VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds (StockStory)
Aug-12-25 06:32AM	FDA gives approval to Viatris for Iron Sucrose Injection (Pharmaceutical Business Review)
Aug-11-25 12:31PM	Why Viatris (VTRS) Stock Is Up Today (StockStory)
09:29AM	Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. (PR Newswire)
Aug-08-25 01:10PM	EpiPen patent expiry opens new era for innovation (Pharmaceutical Technology)
Aug-07-25 05:43PM	Analyst Report: Viatris Inc. (Morningstar Research)
02:39PM	Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars (StockStory)

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Paul	See Remarks	Mar 23 '26	Sale	13.28	21,350	283,539	366,288	Mar 24 06:04 PM
Paul Campbell	Officer	Mar 23 '26	Proposed Sale	13.28	21,350	283,508		Mar 23 04:49 PM
Le Goff Corinne	Chief Commercial Officer	Mar 06 '26	Option Exercise	0.00	46,358	0	101,582	Mar 10 07:04 PM
Mistras Theodora	Chief Financial Officer	Mar 06 '26	Option Exercise	0.00	43,782	0	92,787	Mar 10 07:04 PM
SEVERINO MICHAEL	Director	Mar 06 '26	Option Exercise	0.00	26,031	0	26,031	Mar 10 07:03 PM
PARRISH MARK W	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	165,230	Mar 10 07:03 PM
MARK RICHARD A	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	116,145	Mar 10 07:03 PM
Campbell Paul	See Remarks	Mar 06 '26	Option Exercise	0.00	28,974	0	398,956	Mar 10 07:03 PM
Smith Scott Andrew	Chief Executive Officer	Mar 06 '26	Option Exercise	0.00	130,701	0	1,374,576	Mar 10 07:03 PM
HIGGINS MELINA E	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	146,048	Mar 10 07:03 PM
Groothuis Leo Frans	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	63,567	Mar 10 07:03 PM
SIMMONS DAVID S	Director	Mar 06 '26	Option Exercise	0.00	23,344	0	23,344	Mar 10 07:03 PM
SIMMONS DAVID S	Director	Aug 27 '25	Buy	10.42	286	2,981	970	Mar 10 07:03 PM
SIMMONS DAVID S	Director	Nov 03 '25	Buy	10.43	213	2,221	1,183	Mar 10 07:03 PM
Lyons Dillon JoEllen	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	102,526	Mar 10 07:03 PM
KILTS JAMES M	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	161,257	Mar 10 07:03 PM
Vivaldi Coelho Rogerio	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	46,526	Mar 10 07:03 PM
DAMELIO FRANK A	Director	Mar 06 '26	Option Exercise	0.00	26,031	0	26,031	Mar 10 07:03 PM
CORNWELL W DON	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	112,044	Mar 10 07:03 PM
FINNEY ELISHA W	Director	Mar 06 '26	Option Exercise	0.00	24,835	0	62,667	Mar 10 07:03 PM
Mistras Theodora	Chief Financial Officer	Mar 04 '26	Option Exercise	0.00	34,084	0	66,991	Mar 05 07:00 PM
Le Goff Corinne	Chief Commercial Officer	Mar 04 '26	Option Exercise	0.00	39,773	0	72,019	Mar 05 07:00 PM
Enrietti Andrew	See Remarks	Mar 03 '26	Option Exercise	0.00	110,630	0	248,032	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 04 '26	Option Exercise	0.00	18,720	0	377,939	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 03 '26	Option Exercise	0.00	190,027	0	435,151	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 04 '26	Option Exercise	0.00	101,217	0	1,281,172	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 03 '26	Option Exercise	0.00	1,440,831	0	1,695,045	Mar 05 07:00 PM
Mistras Theodora	Chief Financial Officer	Jan 01 '26	Option Exercise	0.00	25,260	0	48,265	Jan 02 06:00 PM
Le Goff Corinne	Chief Commercial Officer	Sep 11 '25	Sale	10.25	7,032	72,045	35,299	Sep 12 06:00 PM
Le Goff Corinne	Officer	Sep 11 '25	Proposed Sale	10.25	7,032	72,045		Sep 11 08:05 PM
Smith Scott Andrew	Chief Executive Officer	Aug 12 '25	Buy	9.99	22,000	219,740	314,807	Aug 13 06:08 PM
Smith Scott Andrew	Chief Executive Officer	May 12 '25	Buy	8.94	60,000	536,262	292,807	May 14 06:00 PM
Le Goff Corinne	Chief Commercial Officer	Apr 15 '25	Option Exercise	0.00	41,112	0	60,441	Apr 16 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTRS

Viatris Inc

Upgrade your FINVIZ experience